| Primary |
| Psoriasis |
40.0% |
| Diabetes Mellitus |
10.0% |
| Pemphigoid |
10.0% |
| Toxic Skin Eruption |
10.0% |
| Dermatitis |
5.0% |
| Essential Hypertension |
5.0% |
| Hyperlipidaemia |
5.0% |
| Paraneoplastic Pemphigus |
5.0% |
| Product Used For Unknown Indication |
5.0% |
| Prophylaxis |
5.0% |
|
| Dizziness |
10.0% |
| Drug Ineffective |
10.0% |
| Dyspnoea |
10.0% |
| Osteopenia |
10.0% |
| Perivascular Dermatitis |
10.0% |
| Plagiocephaly |
10.0% |
| Pre-existing Disease |
10.0% |
| Skin Atrophy |
10.0% |
| Tremor |
10.0% |
| Whipple's Disease |
10.0% |
|
| Secondary |
| Product Used For Unknown Indication |
20.5% |
| Psoriasis |
15.4% |
| Foetal Exposure During Pregnancy |
9.4% |
| Asthma |
7.7% |
| Respiratory Tract Infection |
7.7% |
| Type 2 Diabetes Mellitus |
3.4% |
| Antiallergic Therapy |
2.6% |
| Atrophic Vulvovaginitis |
2.6% |
| Chronic Hepatitis C |
2.6% |
| Depression |
2.6% |
| Essential Hypertension |
2.6% |
| Fibromyalgia |
2.6% |
| Headache |
2.6% |
| Hypothyroidism |
2.6% |
| Immunosuppression |
2.6% |
| Migraine |
2.6% |
| Myocardial Ischaemia |
2.6% |
| Nausea |
2.6% |
| Oral Disorder |
2.6% |
| Steroid Therapy |
2.6% |
|
| Alopecia |
12.0% |
| Otitis Media Chronic |
8.0% |
| Pain |
8.0% |
| Stress |
8.0% |
| Diabetes Mellitus |
4.0% |
| Dizziness |
4.0% |
| Drug Ineffective |
4.0% |
| Drug Ineffective For Unapproved Indication |
4.0% |
| Hypertension |
4.0% |
| Lacrimation Increased |
4.0% |
| Off Label Use |
4.0% |
| Oropharyngeal Pain |
4.0% |
| Psoriatic Arthropathy |
4.0% |
| Pulmonary Embolism |
4.0% |
| Rash |
4.0% |
| Rash Generalised |
4.0% |
| Rash Pruritic |
4.0% |
| Skin Disorder |
4.0% |
| Thrombosis |
4.0% |
| Tinea Capitis |
4.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.9% |
| Psoriasis |
25.7% |
| Psoriatic Arthropathy |
4.2% |
| Hypertension |
3.5% |
| Pain |
3.3% |
| Asthma |
2.4% |
| Depression |
2.0% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Anxiety |
1.7% |
| Rheumatoid Arthritis |
1.6% |
| Diabetes Mellitus |
1.5% |
| Crohn's Disease |
1.5% |
| Hypersensitivity |
1.4% |
| Drug Use For Unknown Indication |
1.3% |
| Blood Pressure |
1.2% |
| Blood Cholesterol Increased |
1.1% |
| Vitamin Supplementation |
1.1% |
| Back Pain |
1.0% |
| Insomnia |
0.9% |
| Multiple Sclerosis |
0.9% |
|
| Psoriasis |
22.5% |
| Injection Site Pain |
10.8% |
| Drug Ineffective |
10.3% |
| Pain |
4.2% |
| Pulmonary Embolism |
4.2% |
| Rash |
4.2% |
| Injection Site Erythema |
3.8% |
| Injection Site Haemorrhage |
3.8% |
| Headache |
3.3% |
| Injection Site Swelling |
3.3% |
| Pain In Extremity |
3.3% |
| Sinusitis |
3.3% |
| Urticaria |
3.3% |
| Vomiting |
3.3% |
| Weight Increased |
3.3% |
| Therapeutic Response Decreased |
2.8% |
| Thrombocytopenia |
2.8% |
| Wrong Technique In Drug Usage Process |
2.8% |
| Injection Site Reaction |
2.3% |
| Nausea |
2.3% |
|
| Interacting |
| Rash |
66.7% |
| Chronic Hepatitis C |
33.3% |
|
| Drug Interaction |
50.0% |
| Malaise |
50.0% |
|
